0001213900-23-065274.txt : 20230810 0001213900-23-065274.hdr.sgml : 20230810 20230810081559 ACCESSION NUMBER: 0001213900-23-065274 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230810 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230810 DATE AS OF CHANGE: 20230810 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MoonLake Immunotherapeutics CENTRAL INDEX KEY: 0001821586 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39630 FILM NUMBER: 231157280 BUSINESS ADDRESS: STREET 1: DORFSTRASSE 29 CITY: ZUG STATE: V8 ZIP: 6300 BUSINESS PHONE: 41 41 510 8022 MAIL ADDRESS: STREET 1: DORFSTRASSE 29 CITY: ZUG STATE: V8 ZIP: 6300 FORMER COMPANY: FORMER CONFORMED NAME: Helix Acquisition Corp DATE OF NAME CHANGE: 20200818 8-K 1 ea183237-8k_moonlake.htm CURRENT REPORT
0001821586 false 0001821586 2023-08-10 2023-08-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION  13 or 15(d) of the

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): August 10, 2023

 

MOONLAKE IMMUNOTHERAPEUTICS

(Exact Name of Registrant as Specified in Its Charter)

 

Cayman Islands   001-39630   98-1711963

(State or Other Jurisdiction

of Incorporation)

   (Commission File Number)   (IRS Employer
Identification No.)

 

Dorfstrasse 29

6300 Zug

Switzerland

(Address of principal executive offices and Zip Code)

 

41 415108022

(Registrant’s Telephone Number, Including Area Code)

 

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

 

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Class A ordinary share, par value $0.0001 per share   MLTX   The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 2.02. Results of Operations and Financial Condition.

 

On August 10, 2023, Moonlake Immunotherapeutics (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2023. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

This Item 2.02 and the Press Release attached hereto as Exhibit 99.1, insofar as they disclose information regarding the Company’s results of operation and financial condition for the quarter ended June 30, 2023, are being furnished to the Securities and Exchange Commission.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits. The following exhibit is being furnished herewith:

 

Exhibit
Number		   Exhibit Title or Description
99.1   Press release, dated August 10, 2023
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

1

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    MOONLAKE IMMUNOTHERAPEUTICS
     
Date: August 10, 2023 By: /s/ Matthias Bodenstedt
    Name: Matthias Bodenstedt            
  Title: Chief Financial Officer

 

 

2

 

 

 EX-99.1 2 ea183237ex99-1_moonlake.htm PRESS RELEASE, DATED AUGUST 10, 2023

Exhibit 99.1

 

MoonLake Immunotherapeutics Reports Second Quarter 2023 Financial Results and
Provides a Business Update

 

●Achieved landmark milestone with positive results from Phase 2 MIRA trial in hidradenitis suppurativa (HS), suggesting that, as early as week 12, the Nanobody® sonelokimab, relative to placebo, reaches the highest clinical activity among all other therapies tested in similarly stringent pivotal-like trials; top-line 24-week data readout is expected in mid-October 2023

 

●Successfully completed randomization of the target 200 patients several weeks ahead of schedule in its global Phase 2 ARGO trial in active psoriatic arthritis (PsA); top-line 12-week data readout is expected in the first half of November 2023

 

●Raised gross proceeds of approximately $460 million in an upsized public follow-on offering, providing significant new funds to advance the development of sonelokimab and for general corporate purposes

 

ZUG, Switzerland, August 10, 2023 – MoonLake Immunotherapeutics (NASDAQ:MLTX) (“MoonLake” or the “Company”), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced its financial results for the second quarter of 2023.

 

MoonLake continues to make significant progress with the clinical development of sonelokimab, which is currently being investigated in two Phase 2 clinical trials: the first, “MIRA”, in moderate-to-severe hidradenitis suppurativa (HS) and the second, “ARGO”, in active psoriatic arthritis (PsA). Sonelokimab has already been successfully assessed in a randomized, placebo-controlled, Phase 2b trial in patients with moderate-to-severe plaque-type psoriasis, in which it demonstrated a rapid and durable skin clearance (Psoriasis Area Severity Index (PASI) 100 response). Sonelokimab is an investigational Nanobody® designed to inhibit IL-17F in addition to IL-17A and therefore could represent a major improvement in treating inflammation in these dermatological and rheumatological diseases. The Nanobody’s® smaller size versus traditional antibodies and its albumin-binding domain provide an opportunity for further efficacy. The MIRA and the ARGO trials both achieved their target patient enrollment and randomization faster than anticipated, reflecting the Company’s strong execution and interest from physicians and patients in MoonLake’s clinical development programs.

 

Dr. Jorge Santos da Silva, Chief Executive Officer of MoonLake Immunotherapeutics, said: “This quarter has been transformational for MoonLake. The positive Phase 2 results from our MIRA trial were a landmark milestone. We look ahead with confidence to a number of key catalysts for sonelokimab this year, including the final 24-week data in HS, expected in mid-October, and the topline 12-week data in active PsA, expected in the first half of November, and to creating long-term value for both patients and shareholders.”

 

Second Quarter 2023 Business Highlights (including Post-Quarter End):

 

●On April 19, MoonLake held a Capital Markets Day, which featured a series of presentations from its executive team, who provided a look to the year ahead at near-term catalysts and a financial update. External speaker, Professor Kenneth B. Gordon, Chair of Dermatology at the Medical College of Wisconsin, provided an update on the treatment landscape for HS, reflecting on data and key takeaways from the American Academy of Dermatology Annual Meeting.

 

●On May 3, MoonLake announced a collaboration agreement with SHL Medical to develop an autoinjector for clinical and potential subsequent commercial supply of MoonLake’s Nanobody® sonelokimab.

 

●On June 25, MoonLake announced it achieved a landmark milestone with positive top-line 12-week data readout from its global Phase 2 MIRA trial evaluating the efficacy and safety of the Nanobody® sonelokimab in patients with moderate-to-severe HS. The trial met its primary endpoint with a significantly greater proportion of patients treated with both sonelokimab 120mg and 240mg achieving Hidradenitis Suppurativa Clinical Response (HiSCR) 75 compared to those on placebo at week 12. The results suggest that, as early as week 12, the Nanobody® sonelokimab, relative to placebo, reaches the highest clinical activity among all other therapies tested in similarly stringent pivotal-like trials.

 

●On July 25 (post period-end), MoonLake announced that:

 

◦it successfully completed randomization of the target 200 patients ahead of schedule in its global Phase 2 ARGO trial in active PsA; and

 

◦a Capital Markets Day will be held on September 11, 2023 to discuss the PsA market and to share expectations on the ARGO 12-week data readout in PsA (results expected in the first half of November 2023) and the MIRA 24-week data readout in HS (results expected in mid-October 2023).

 

 

 

 

Second Quarter 2023 Financial Highlights:

 

●On June 30, 2023, MoonLake closed a public offering of 8,000,000 Class A Ordinary Shares at a public offering price of $50.00 per Share. MoonLake also granted the underwriters of this offering the option to purchase up to an additional 1,200,000 Class A Ordinary Shares at the public offering price less the underwriting discounts and commissions, and this option was exercised in full, bringing total gross proceeds of this offering to $460 million.

 

●In addition, during the three months ended June 30, 2023, MoonLake sold 544,894 Class A Ordinary Shares through an At-the-Market facility, yielding gross proceeds of $15.2 million.

 

●As of June 30, 2023, MoonLake held cash and cash equivalents and short-term marketable debt securities of $501.8 million, compared to $63.1 million as of March 31, 2023.

 

●Research and development expenses for the quarter ended June 30, 2023, were $8.7 million, compared to $7.4 million in the previous quarter. The increase was primarily driven by expenses for the conduct of the MIRA and ARGO studies.

 

●General and administrative expenses for the quarter ended June 30, 2023, were $4.5 million, compared to $5.5 million in the previous quarter. The decrease was primarily driven by lower expenses for professional services and share-based compensation.

 

Matthias Bodenstedt, Chief Financial Officer of MoonLake Immunotherapeutics, said: “The past quarter has seen MoonLake raise significant new funds, enabling us to fund the advancement of sonelokimab into multiple Phase 3 programs and putting us in a very strong position for the next phase of growth. We welcome our new shareholders who recognize the value of our Nanobody® and are as excited as we are by our continued advancement of sonelokimab’s clinical development to address some of the fastest growing markets in inflammatory diseases.”

 

Important upcoming anticipated events and next expected data readouts for MoonLake:

 

September:

 

●Capital Markets Day to discuss PsA market and provide guidance for upcoming 12-week ARGO PsA and 24-week MIRA HS readouts

 

October:

 

●MIRA trial top-line 12-week data to be presented at a scientific meeting

 

●R&D Day virtual webcast to share top-line 24-week MIRA HS trial data and Phase 3 plans in HS

 

November:

 

●R&D Day virtual webcast to share top-line 12-week ARGO PsA trial data

 

December:

 

●End of Phase 2 meeting with the FDA to discuss Phase 2 HS data and Phase 3 development plan

 

Early 2024:

 

●R&D Day to share the final Phase 3 plans and other clinical and business catalysts in 2024 and beyond

 

Calendar of upcoming investor conferences in the second half of 2023:

 

●Wedbush 2023 PacGrow Healthcare Conference: August 8-9

 

●Wells Fargo Healthcare Conference 2023: September 6-8

 

●Stifel 2023 Immunology & Inflammation Virtual Summit: September 19

 

●Cantor Fitzgerald Global Healthcare Conference 2023: September 26-28

 

●Guggenheim Securities 5th Annual Inflammation & Immunology Conference: November 6-7

 

●UBS Biopharma Conference 2023: November 8-9

 

●Jefferies London Healthcare Conference 2023: November 14-16

 

2

 

 

About MoonLake Immunotherapeutics

 

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company unlocking the potential of sonelokimab, a novel investigational Nanobody® for the treatment of inflammatory disease, to revolutionize outcomes for patients. Sonelokimab inhibits IL-17A and IL-17F by inhibiting the IL-17A/A, IL-17A/F, and IL-17F/F dimers that drive inflammation. The company’s focus is on inflammatory diseases with a major unmet need, including hidradenitis suppurativa and psoriatic arthritis – conditions affecting millions of people worldwide with a large need for improved treatment options. MoonLake was founded in 2021 and is headquartered in Zug, Switzerland. Further information is available at www.moonlaketx.com.

 

About Nanobodies®

 

Nanobodies® represent a new generation of antibody-derived targeted therapies. They consist of one or more domains based on the small antigen-binding variable regions of heavy-chain-only antibodies (VHH). Nanobodies® have a number of potential advantages over traditional antibodies, including their small size, enhanced tissue penetration, resistance to temperature changes, ease of manufacturing, and the ability to design multivalent therapeutic molecules with bespoke target combinations.

 

About Sonelokimab

 

Sonelokimab (M1095) is an investigational ~40 kDa humanized Nanobody® consisting of three VHH domains covalently linked by flexible glycine-serine spacers. With two domains, sonelokimab selectively binds with high affinity to IL-17A and IL-17F, thereby inhibiting the IL-17A/A, IL-17A/F, and IL-17F/F dimers. A third central domain binds to human albumin, facilitating further enrichment of sonelokimab at sites of inflammatory edema.

 

Sonelokimab is currently being assessed in two ongoing trials, the Phase 2 MIRA trial in HS and the Phase 2 ARGO trial in PsA. The MIRA trial met its primary endpoint, the Hidradenitis Suppurativa Clinical Response (HiSCR) 75 which is a higher measure of clinical response versus the HiSCR50 measure used in other clinical trials. A significantly greater proportion of patients treated with both sonelokimab 120mg and 240mg achieved HiSCR75 compared to those on placebo at week 12. The positive results suggest that, as early as week 12, sonelokimab, relative to placebo, reaches the highest clinical activity among all other therapies tested in similarly stringent pivotal-like trials. The trial proceeds to week 24, with a 4-week safety follow-up.

 

Sonelokimab has also been assessed in a randomized, placebo-controlled Phase 2b trial in 313 patients with moderate-to-severe plaque-type psoriasis. Sonelokimab demonstrated a rapid and durable clinical response (Investigator’s Global Assessment Score 0 or 1, Psoriasis Area and Severity Index 90/100) in patients with moderate-to-severe plaque-type psoriasis. Sonelokimab was generally well tolerated, with a safety profile similar to the active control, secukinumab (Papp KA, et al. Lancet. 2021; 397:1564-1575).

 

In an earlier Phase 1 trial in patients with moderate-to-severe plaque-type psoriasis, sonelokimab has been shown to decrease (to normal skin levels) the cutaneous gene expression of pro-inflammatory cytokines and chemokines (Svecova D. J Am Acad Dermatol. 2019;81:196–203). Recently, a global phase 2 trial in psoriatic arthritis (NCT05640245, M1095-PSA-201, “ARGO”) including multiple arms and over 200 patients has been initiated.

 

Sonelokimab is not yet approved for use in any indication.

 

About the MIRA trial

 

The MIRA trial (M1095-HS-201) is a global, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of the Nanobody® sonelokimab, administered subcutaneously, in the treatment of adult patients with active moderate to severe HS. The trial recruited 234 patients, with the aim to evaluate two different doses of sonelokimab, with placebo control and adalimumab as an active reference arm. The primary endpoint of the trial is the percentage of participants achieving Hidradenitis Suppurativa Clinical Response 75 (HiSCR75), defined as a ≥75% reduction in total abscess and inflammatory nodule (AN) count with no increase in abscess or draining tunnel count relative to baseline. The trial also evaluates a number of secondary endpoints, including the proportion of patients achieving HiSCR50, the change from baseline in International Hidradenitis Suppurativa Severity Score System (IHS4), the proportion of patients achieving a Dermatology Life Quality Index (DLQI) total score of ≤5, and the proportion of patients achieving at least 30% reduction from baseline in Numerical Rating Scale (NRS30) in the Patient’s Global Assessment of Skin Pain (PGA Skin Pain). Further details are available on: https://www.clinicaltrials.gov/ct2/show/NCT05322473

 

3

 

 

About the ARGO trial

 

The ARGO trial (M1095-PSA-201) is a global, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of the Nanobody® sonelokimab, administered subcutaneously, in the treatment of adult patients with active PsA. The trial is designed to evaluate different doses of sonelokimab, with placebo control and adalimumab as an active reference arm. The primary endpoint of the trial is the percentage of participants achieving ≥50% improvement in signs and symptoms of disease from baseline, compared to placebo, as measured by the American College of Rheumatology (ACR) 50 response. The trial also evaluates a number of secondary endpoints, including improvement compared to placebo in ACR70, complete skin clearance as measured by at least a 100% improvement in the Psoriasis Area and Severity Index, physical function as measured by the Health Assessment Questionnaire-Disability Index, enthesitis as measured by the Leeds Enthesitis Index and pain as measured by the Patients Assessment of Arthritis Pain. Further details are available on: https://clinicaltrials.gov/ct2/show/NCT05640245

 

Cautionary Statement Regarding Forward Looking Statements

 

This press release contains certain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding MoonLake’s expectations, hopes, beliefs, intentions or strategies regarding the future including, without limitation, statements regarding: plans for and timing of clinical trials, including expectations regarding the timing and outcome of the MIRA and ARGO trials, the efficacy and safety of sonelokimab for the treatment of HS and PsA, including in comparison to existing standards or care or other competing therapies, clinical trials and research and development programs and the anticipated timing of the results from those studies and trials, the timing for meeting with regulatory authorities and our anticipated cash usage and the period of time we anticipate such cash to be available. In addition, any statements that refer to projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions, are forward- looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that statement is not forward looking.

 

Forward-looking statements are based on current expectations and assumptions that, while considered reasonable by MoonLake and its management, as the case may be, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with MoonLake’s business in general and limited operating history; expectations regarding the timing and outcome of the MIRA and ARGO trials; positive results from a clinical trial may not necessarily be predictive of the results of future or ongoing clinical studies; MoonLake’s substantial dependence on the success of its Nanobody® sonelokimab; state and federal healthcare reform measures that could result in reduced demand for MoonLake’s product candidates and reliance on third parties to conduct and support its preclinical studies and clinical trials.

 

Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. MoonLake does not undertake or accept any duty to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or in the events, conditions or circumstances on which any such statement is based.

 

CONTACT

 

MoonLake Immunotherapeutics Investors

 

Matthias Bodenstedt, CFO

ir@moonlaketx.com

 

MoonLake Immunotherapeutics Media

 

Patricia Sousa, Director Corporate Affairs

media@moonlaketx.com

 

Consilium Strategic Communications

 

Mary-Jane Elliott, Ashley Tapp,

Namrata Taak

Tel: +44 (0) 20 3709 5700

media@moonlaketx.com

 

4

 

 

MOONLAKE IMMUNOTHERAPEUTICS

CONDENSED CONSOLIDATED BALANCE SHEETS

 

(Amounts in USD, except share data)

 

   June 30,
2023
(Unaudited)		   March 31,
2023
(Unaudited)		 
Current assets        
Cash and cash equivalents  $501,786,997   $50,129,197 
Short-term marketable debt securities   —    12,920,960 
Other receivables   619,767    378,445 
Prepaid expenses   3,960,383    3,075,862 
Total current assets   506,367,147    66,504,464 
           
Non-current assets          
Operating lease right-of-use assets   211,238    246,256 
Property and equipment, net   42,810    46,099 
Total non-current assets   254,048    292,355 
Total assets  $506,621,195   $66,796,819 
           
Current liabilities          
Trade and other payables  $4,359,923   $3,827,403 
Short-term portion of operating lease liabilities   158,221    155,173 
Accrued expenses and other current liabilities   2,616,482    3,296,839 
Total current liabilities   7,134,626    7,279,415 
           
Non-current liabilities          
Long-term portion of operating lease liabilities   53,017    91,081 
Pension liability   323,597    314,174 
Total non-current liabilities   376,614    405,255 
Total liabilities   7,511,240    7,684,670 
Commitments and contingencies (Note 15)          
           
Equity (deficit)          
Class A Ordinary Shares: $0.0001 par value; 500,000,000 shares authorized; 53,486,810 shares issued and outstanding as of June 30, 2023; 39,154,203 shares issued and outstanding as of March 31, 2023   5,349    3,916 
Class C Ordinary Shares: $0.0001 par value; 100,000,000 shares authorized; 8,959,195 shares issued and outstanding as of June 30, 2023; 13,546,908 shares issued and outstanding as of March 31, 2023   896    1,355 
Additional paid-in capital   589,549,979    131,308,849 
Accumulated deficit   (99,794,347)   (89,655,068)
Accumulated other comprehensive income   35,124    340,108 
Total shareholders’ equity (deficit)   489,797,001    41,999,160 
Noncontrolling interests   9,312,954    17,112,989 
Total equity   499,109,955    59,112,149 
Total liabilities and equity  $506,621,195   $66,796,819 

 

5

 

 

MOONLAKE IMMUNOTHERAPEUTICS

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(Unaudited)

 

(Amounts in USD, except share and per share data)

 

   For the Three Months
Period Ended		   For the
Six Months
Period
Ended		 
   June 30,   March 31,   June 30, 
   2023   2023   2023 
Operating expenses            
Research and development  $(8,703,849)  $(7,415,097)  $(16,118,949)
General and administrative   (4,482,041)   (5,516,469)   (9,998,510)
Total operating expenses   (13,185,890)   (12,931,566)   (26,117,459)
Operating loss   (13,185,890)   (12,931,566)   (26,117,459)
                
Other income, net   842,652    723,589    1,566,242 
Loss before income tax   (12,343,238)   (12,207,977)   (24,551,217)
                
Income tax expense   (10,149)   (11,010)   (21,157)
Net loss  $(12,353,387)  $(12,218,987)  $(24,572,374)
Of which: net loss attributable to controlling interests shareholders   (10,139,279)   (9,004,856)   (19,144,135)
Of which: net loss attributable to noncontrolling interests shareholders   (2,214,108)   (3,214,131)   (5,428,239)
                
Net unrealized loss on marketable securities and short term investments   (415,225)   24,472    (390,753)
Actuarial gain (loss) on employee benefit plans   (16,336)   (42,144)   (58,481)
Other comprehensive income (loss)   (431,561)   (17,672)   (449,234)
Comprehensive loss  $(12,784,948)  $(12,236,659)  $(25,021,608)
Comprehensive loss attributable to controlling interests shareholders   (10,488,185)   (9,017,481)   (19,505,667)
Comprehensive loss attributable to noncontrolling interests   (2,296,763)   (3,219,178)   (5,515,941)
                
Weighted-average number of Class A Ordinary Shares, basic and diluted   43,718,464    39,061,977    41,403,084 
Basic and diluted net loss per share attributable to controlling interests shareholders  $(0.23)  $(0.23)  $(0.46)

 

 

6

 

 

 EX-101.SCH 3 mltx-20230810.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 mltx-20230810_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 mltx-20230810_pre.xml XBRL PRESENTATION FILE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Cover
Aug. 10, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 10, 2023
Entity File Number 001-39630
Entity Registrant Name MOONLAKE IMMUNOTHERAPEUTICS
Entity Central Index Key 0001821586
Entity Tax Identification Number 98-1711963
Entity Incorporation, State or Country Code E9
Entity Address, Address Line One Dorfstrasse 29
Entity Address, City or Town Zug
Entity Address, Country CH
Entity Address, Postal Zip Code 6300
City Area Code 41
Local Phone Number 415108022
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Class A ordinary share, par value $0.0001 per share
Trading Symbol MLTX
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
XML 7 ea183237-8k_moonlake_htm.xml IDEA: XBRL DOCUMENT 0001821586 2023-08-10 2023-08-10 iso4217:USD shares iso4217:USD shares 0001821586 false 8-K 2023-08-10 MOONLAKE IMMUNOTHERAPEUTICS E9 001-39630 98-1711963 Dorfstrasse 29 6300 Zug CH 41 415108022 false false false false Class A ordinary share, par value $0.0001 per share MLTX NASDAQ true false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( /U!"E<'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " #]00I7W2&N>N\ K @ $0 &1O8U!R;W!S+V-O&ULS9)1 M2\,P$,>_BN2]O:9U(J'+BV-/"H(#Q;>0W+9@DX;DI-VW-ZU;A^@'\#%W__SN M=W"M#D+W$9]C'S"2Q70SNLXGH<.:'8F" $CZB$ZE,B=\;N[[Z!3E9SQ 4/I# M'1#JJKH#AZ2,(@43L @+DWI\65>M[ ^ MD?(:\Z]D!9T"KMEE\FOSL-EMF:RKNBFJ^X)7.UX+OA*KV_?)]8??5=CUQN[M M/S:^",H6?MV%_ )02P,$% @ _4$*5YE&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R M> +]O6N[!3+ MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,! M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2 MBW A(5M>5 TR M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$ MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH] M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9 M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+ MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+ M.7\N?<^E[[GT/:'2MSAD6R4)RU3393>* M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_# M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0 MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYNTB42%(JP# 4A M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_ M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]! MU4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04 M" #]00I7T3?O9'($ F$0 & 'AL+W=OZT#R8Q8-TDSFRGM/]^ MQX$F; TG?($XR7EY?'S\VJ:WE>J[WG!NR%L2I[KO;(S);EQ7AQN>,'TA,Y[" MDY54"3/05&M79XJSJ A*8M?WO(Z;,)$Z@UYQ;Z8&/9F;6*1\IHC.DX2I]R\\ MEMN^0YV/&\]BO3'VACOH96S-Y]R\9#,%+;=4B43"4RUD2A1?]9V WGSQVS:@ M>.,/P;?ZX)K8KBRE_&X;XZCO>):(QSPT5H+!URL?\CBV2L#QSU[4*7_3!AY> M?ZC?%9V'SBR9YD,9?Q61V?2=KD,BOF)Y;)[E]I[O.U0 AC+6Q2?9[MYM>PX) M:T#*WG##?=B779A_)"S(UQ>$>F?$]_S6?\-= M("@Q_!+#+_1:& ;Y*UAJHV"@_JXCVBE-U<'AX]_P!@;@L(2Y1E0 (HH+B+F;K.@H\ M?L5BS1&.=LG1/BT9,ZZ$C,@HC0@47VU><*6RC)KJJ%.B=5#!46J$>2=W(N9D MFB?+^MK&-3R/GK>N.RT/X;DJ>:Y.X7GF:V$K&W(V94EMHG"=R=/3]#%X&)'Q M9/(R?5KAE,1[.$UZ?M M;@?!NBZQKD_!6K W,HZ 3:Q$R HO/SZTN.)U]YQ>40J#B^!1K_).[Q3 <1I* ME4E5L)V1N8&Y0*0B0YE#0B&O,JH=\B;U:PSRP.#I*9!!%($MZK./"_(([Y&G MM)X,E[R5:F7+66M.?)2R\G^*VOEW/]S&D:A6@N'U_5<(8GD)B MDB1/]RZF:[%PH:8EG%:63W&GGLM8A,*(=$TFX%=*L+B6!U=IY*F\GN+6/%/\ M/(3T\#3DNYT6;'9@3_BT6AT90%ROB2*1P2"-ZPQ0_(QE3Y)7% M.2<_>A=VC2<9]+QXB/7@8/>/V_5"L?[)WG^*.%J;;/T&RB8C363C*7UPXP+ M&I6CXU99OH\[]L@>KGE$IA+FJR0OL!\P&PZY,W9N1 3&%<[OQ99M=U:HA<5_ MX^@\<0].O?8?A FSZ=$DYBL0\BZN0%?M#N6[AI%9<1!>2@/'ZN)RPQG,8?L" M/%]):3X:]FQ=_C4R^!=02P,$% @ _4$*5Y^@&_"Q @ X@P T !X M;"]S='EL97,N>&ULW5=M:]LP$/XK0C]@;F)JXI$8MD!AL(U"\V%?E5AV!'KQ M9+ES^NNGLVPG:75EW8>QS:')W3VZNT=W)YFN6W>2_.'(N2.]DKK=T*-SS?LD M:0]'KEC[SC1<>Z0R5C'G55LG;6,Y*UMP4C)9WMQDB6)"TV*M.W6G7$L.IM-N M0V]H4JPKH\^6E :#7\H4)X],;NB62;&W8EC+E)"G8%Z"X6"DL<1Y*GQ#%V!I MGP*\"!JP'.,HH8T%8Q(RA._]N/P9,&FM5X64,\$E#89BW3#GN-5W7AD6#\87 M$!GEW:GQ#&O+3HOE+3T[##\^R=[8DMLYS8).IF(M>05TK*B/\.M,DP#HG%%> M* 6KC68#A\EC%'S8 Y?R 5KXK;J*W5B'_2^FO-CT1=X=-8T\O1!BEHK'O;^ MRPF+-9O\R-%8\>2SP:0)P:?EA6;/CO9NFJ:]PSLM_D/.?K7/- M-;=,7I+VH_\W5_DMC)/Q]%PZC+N.HL?X;[:)'-M[#/ M)73)>UYN1]76^T$D7O!9QP<&%Y_J?]K-#] M! SCMHHB*]1GA?H$KQBR'3Y8GKA/[I_X3O,\3;,,J^AV&V6PQ>J69? 7CX9Q M P\L#V1Z6ZWQ;N,3\OH<8#U];4*PG>*3B.T4KS4@\;J!1Y['NXWE 0^L"]CL M0/YX'IBIN$^:0ERHY_U=3_ 102P,$% @ _4$*5Y>*NQS M $P( L !?3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/ M:(7->=I3W;+T]!;X"O M.DQQ0FE(2S,.\,W2?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_ M'B4 M?'D78FYJD6:>IK&HP=MX1PT$G53$WHI"/J:Q8;!EK '$NW2:9;/46PQFN1BU MMIS> A(H!"DHV1%[A$O\G7D(GP&LK\,S4-AB.G8RF2&]B]#V,YU#BG/]3(U45%K"FHO409.B1P74& M0ZRQB28)UD-N5G0&[O+H YMRR"9JZJ8IGJ,.>%,.]D9/)508H'Q3F:B\]E-L M.>F.7F=Z_S!YU!Y:YU;*O8=7LN48Y0]02P,$% @ _4$*5R0>FZ*M M ^ $ !H !X;"]?+7_OR4Z?:!1W;J"V M\R1&:P;*9,OL[P"D6[2*+L[C,$]J%ZSB688&O-*]:A"2*+I!V#-DGNZ9HIP\ M_D-T==UI?#C]LCCP#S"\7>BI160I2A4:Y$S":+8VP5+BRTR6HJ@R&8HJEG!: M(.+)(&UI5GVP3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L#!!0 ( /U!"E=E MD'F2&0$ ,\# 3 6T-O;G1E;G1?5'EP97-=+GAM;*V334[#,!"%KQ)E M6R4N+%B@IAM@"UUP 6-/&JO^DV=:TMLS3MI*H!(5A4VL>-Z\SYZ7K-Z/$;#H MG?78E!U1?!0"50=.8ATB>*ZT(3E)_)JV(DJUDUL0]\OE@U#!$WBJ*'N4Z]4S MM')OJ7CI>1M-\$V9P&)9/(W"S&I*&:,U2A+7Q<'K'Y3J1*BY<]!@9R(N6%"* MJX1<^1UPZGL[0$I&0[&1B5ZE8Y7HK4 Z6L!ZVN+*&4/;&@4ZJ+WCEAIC JFQ M R!GZ]%T,4TFGC",S[O9_,%F"LC*30H1.;$$?\>=(\G=560C2&2FKW@ALO7L M^T%.6X.^DN\ K @ M$0 @ &O 9&]C4')O<',O8V]R92YX;6Q02P$"% ,4 M" #]00I7F5R<(Q & "<)P $P @ '- 0 >&PO=&AE;64O M=&AE;64Q+GAM;%!+ 0(4 Q0 ( /U!"E?1-^]D<@0 "81 8 M " @0X( !X;"]W;W)K&PO7BKL

JQ"(6,P$ "(" / M " 7L0 !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4 " #] M00I7)!Z;HJT #X 0 &@ @ ';$0 >&PO7W)E;',O=V]R M:V)O;VLN>&UL+G)E;'-02P$"% ,4 " #]00I799!YDAD! #/ P $P M @ ' $@ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 "0 ) + #X" *% ! end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://moonlaketx.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ea183237-8k_moonlake.htm ea183237ex99-1_moonlake.htm mltx-20230810.xsd mltx-20230810_lab.xml mltx-20230810_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ea183237-8k_moonlake.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "ea183237-8k_moonlake.htm" ] }, "labelLink": { "local": [ "mltx-20230810_lab.xml" ] }, "presentationLink": { "local": [ "mltx-20230810_pre.xml" ] }, "schema": { "local": [ "mltx-20230810.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "MLTX", "nsuri": "http://moonlaketx.com/20230810", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "ea183237-8k_moonlake.htm", "contextRef": "From2023-08-10to2023-08-10", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://moonlaketx.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "ea183237-8k_moonlake.htm", "contextRef": "From2023-08-10to2023-08-10", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://moonlaketx.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://moonlaketx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://moonlaketx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://moonlaketx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://moonlaketx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://moonlaketx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://moonlaketx.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://moonlaketx.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://moonlaketx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://moonlaketx.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://moonlaketx.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://moonlaketx.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://moonlaketx.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://moonlaketx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://moonlaketx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://moonlaketx.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://moonlaketx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://moonlaketx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://moonlaketx.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://moonlaketx.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://moonlaketx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://moonlaketx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://moonlaketx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://moonlaketx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://moonlaketx.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://moonlaketx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://moonlaketx.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://moonlaketx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://moonlaketx.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://moonlaketx.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://moonlaketx.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://moonlaketx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://moonlaketx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://moonlaketx.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://moonlaketx.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://moonlaketx.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://moonlaketx.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://moonlaketx.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://moonlaketx.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://moonlaketx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://moonlaketx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://moonlaketx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://moonlaketx.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://moonlaketx.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://moonlaketx.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://moonlaketx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://moonlaketx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://moonlaketx.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://moonlaketx.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://moonlaketx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://moonlaketx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://moonlaketx.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://moonlaketx.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://moonlaketx.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://moonlaketx.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://moonlaketx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://moonlaketx.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://moonlaketx.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 14 0001213900-23-065274-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-23-065274-xbrl.zip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end